# Body Weight, Aspirin Dose and Pro-resolving Mediators

> **NCT04697719** · PHASE4 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 103 (actual)

## Conditions studied

- Body Weight

## Interventions

- **DRUG:** Aspirin 81mg
- **DRUG:** Aspirin 325mg

## Key facts

- **NCT ID:** NCT04697719
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-04
- **Primary completion:** 2025-01-29
- **Final completion:** 2025-01-29
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04697719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04697719, "Body Weight, Aspirin Dose and Pro-resolving Mediators". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04697719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*